Mohammad Eldeeb, MD
Interventional Pain Medicine · Fort Smith, ARNPI 1932213568
Payments from drug & device makers
Across 471 payments — averaging $569.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- H. Lundbeck A S$259K
- Nevro Corp.$2K
- Boston Scientific$2K
- Biohaven Pharmaceuticals, Inc.$1K
- AbbVie$726
- Collegium Pharmaceutical, Inc.$339
- plus $2K from 28 others
What the payments were for
- Consulting fees$1,20014%
- Travel & lodging$94111%
- Food & beverage$6,48775%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| H. Lundbeck A S | 58 | $259,453 |
| Nevro Corp. | 172 | $2,378 |
| Boston Scientific | 54 | $1,679 |
| Biohaven Pharmaceuticals, Inc. | 4 | $1,308 |
| AbbVie(2 entities) | 46 | $726 |
| Collegium Pharmaceutical, Inc. | 17 | $339 |
| Scilex Pharmaceuticals Inc. | 20 | $332 |
| Pfizer | 14 | $286 |
| Teva Pharmaceuticals USA, Inc. | 19 | $236 |
| Amgen(2 entities) | 8 | $150 |
| Medtronic(2 entities) | 5 | $134 |
| Abbott | 3 | $125 |
| Novartis | 6 | $124 |
| Lilly USA, LLC | 8 | $116 |
| SPR Therapeutics, Inc | 1 | $103 |
| Si-bone, Inc. | 3 | $72 |
| GRT US Holding, Inc. | 4 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $64 |
| IBSA Pharma Inc. | 2 | $44 |
| Arbor Pharmaceuticals, Inc. | 2 | $43 |
| Averitas Pharma Inc. | 2 | $40 |
| Bioventus LLC | 1 | $40 |
| Hikma Pharmaceuticals USA | 2 | $35 |
| Relievant Medsystems, Inc. | 2 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Stryker | 1 | $21 |
| Nalu Medical, Inc. | 2 | $20 |
| Globus Medical | 1 | $18 |
| GE HealthCare | 1 | $18 |
| Pacira Therapeutics, Inc. | 1 | $17 |
| Pacira Pharmaceuticals Incorporated | 1 | $17 |
| Biodelivery Sciences International, Inc. | 1 | $14 |
| Stimwave Technologies Incorporated | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$268,101 in reported general payments places this provider in the 95th percentile of 29 interventional pain medicine providers in Arkansas.
See all interventional pain medicine providers in Arkansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 1,729 | $51,394 |
| Xtampza ErOxycodone Myristate | 86 | $48,580 |
| QutenzaCapsaicin/Skin Cleanser | 14 | $43,214 |
| BelbucaBuprenorphine Hcl | 32 | $24,665 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,163 | $22,194 |
| Fentanyl | 108 | $10,082 |
| Morphine Sulfate ErMorphine Sulfate | 315 | $6,628 |
| Tramadol Hcl | 813 | $6,601 |
| Pregabalin | 320 | $6,114 |
| Lidocaine | 74 | $5,814 |
| Naloxone Hcl | 77 | $4,926 |
| Gabapentin | 304 | $4,092 |
| Oxycodone Hcl | 257 | $3,923 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 21 | $3,314 |
| Tramadol Hcl ErTramadol Hcl | 64 | $2,818 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca | $339 | $73,245118 claims |
| GRT US Holding, Inc.Qutenza | $71 | $43,21414 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Morphine Sulfate | $35 | $4,43958 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 29 interventional pain medicine providers in Arkansas.
Other interventional pain medicine in Fort Smith
- Brett WhatcottFort Smith$10K
- Thomas de MirandaFort Smith$4K
- Sameer JainBryant$56K
- Ryan KrafftMountain Home$51K
- Robert CannonFayetteville$15K
- Amir QureshiLittle Rock$14K
- Ahmed GhalebLittle Rock$7K
- Michael AdamsMena$6K
- Majid SaleemLittle Rock$5K
- Gary FrankowskiLittle Rock$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.